Lordes (desloratadine) coated tablets 5 mg. №20

Description

Lordes composition 
active substance: desloratadine;
1 tablet contains desloratadine 5 mg;
Excipients: calcium hydrogen phosphate, microcrystalline cellulose, corn starch, talc, Opadry II Blue 85F20578 coating: polyvinyl alcohol, polyethylene glycol, titanium dioxide (E 171), indigo carmine (E 132), iron oxide yellow and E2.

Dosage form
Coated tablets.

Pharmacological properties
Desloratadine is a selective blocker of peripheral histamine H1-receptors that does not cause a sedative effect. Desloratadine is the primary active metabolite of loratadine. Following oral administration, desloratadine selectively blocks peripheral H1-histamine receptors and does not cross the blood-brain barrier.

Indication:

• to relieve the symptoms associated with allergic rhinitis, such as sneezing, runny nose, itching, swelling and nasal congestion, as well as itching and redness of the eyes, tearing, itching in the palate and cough;
• to relieve urticaria-related symptoms such as itching and rash.

Contraindication
Hypersensitivity to the active substance or to any of the excipients or to loratadine.

Children
The efficacy and safety of desloratadine tablets for children under 12 years of age have not been established.

Use during pregnancy or breastfeeding
Desloratadine has not been shown to be teratogenic in animal studies. The safety of the drug during pregnancy has not been established. Therefore, the use of the drug during pregnancy is not recommended.
Desloratadine passes into breast milk, so the drug is not recommended for women who are breast-feeding.

Method of application and dosage
Lordes is for oral use. Adults and children over 12 years of age should take 1 tablet (5 mg) once a day, regardless of food intake. The tablet should be swallowed whole with water. Lordes are preferably taken regularly, at the same time of day.
The duration of treatment is determined by the severity and course of the disease.

• Treatment of intermittent allergic rhinitis (symptoms less than 4 days a week or less than 4 weeks) should be based on medical history: discontinue after symptoms resolve and resume after recurrence.
• In persistent allergic rhinitis (symptoms for more than 4 days a week or more than 4 weeks), treatment should be continued throughout the allergen period.

Overdose
No clinically relevant adverse reactions were observed in clinical trials in which desloratadine was administered at doses of 45 mg (9 times the recommended dose). Accidental ingestion of large doses of Lordes® may increase the side effects – fatigue, dry mouth, headache, tachycardia.
Treatment. In case of overdose, take standard measures to remove the unabsorbed active substance. Symptomatic and supportive treatment is recommended. Desloratadine is not removed by hemodialysis; the possibility of its removal during peritoneal dialysis is not established.

Side effects:

• Mental disorders: hallucinations.
• From the nervous system: dizziness, drowsiness, insomnia, psychomotor hyperactivity, convulsions.
• From the heart: tachycardia, palpitations.
• From the gastrointestinal tract: abdominal pain, nausea, vomiting, dyspepsia, diarrhea.
• From the hepatobiliary system: increased levels of liver enzymes, elevated bilirubin, hepatitis.
• From the musculoskeletal system and connective tissue: myalgia.
• Common disorders: hypersensitivity reactions, including anaphylaxis, Quincke’s edema, dyspnea, pruritus, rash, urticaria.

Expiration date
2 years.

Storage conditions
Store at a temperature not exceeding 25 ° C in the original package.
Keep out of reach of children.